[Chinese consensus for the bispeific T cell engager in the treatment of B-cell acute lymphoblastic leukemia (2022)]

. 2022 Jun 14;43(6):448-455.

doi: 10.3760/cma.j.issn.0253-2727.2022.06.002.

[Article in Chinese]

[Article in Chinese]

Union for China Leukemia & Lymphoma Investigators of Chinese Society of Clinical Oncology et al. Zhonghua Xue Ye Xue Za Zhi. 2022.

. 2022 Jun 14;43(6):448-455.

doi: 10.3760/cma.j.issn.0253-2727.2022.06.002.

No abstract available

Cited by

Short-course blinatumomab for refractory/relapse precursor B acute lymphoblastic leukemia in children.
Xie J, Liu S, Zhou M, Wang Y, He H, Xiao P, Hu S, Lu J. Xie J, et al. Front Pediatr. 2023 Aug 4;11:1187607. doi: 10.3389/fped.2023.1187607. eCollection 2023. Front Pediatr. 2023. PMID: 37601130 Free PMC article.
[Chinese consensus for the bispecific T cell engager in the treatment of acute lymphoblastic leukemia (2024)].
Union for China Leukemia of Chinese Society of Clinical Oncology; Union for Lymphoma Investigators of Chinese Society of Clinical Oncology; Chinese Society of Hematology, Chinese Medical Association; Chinese Hematology Association, Chinese Medical Doctor Association. Union for China Leukemia of Chinese Society of Clinical Oncology, et al. Zhonghua Xue Ye Xue Za Zhi. 2024 Jul 14;45(7):629-636. doi: 10.3760/cma.j.cn121090-20240528-00194. Zhonghua Xue Ye Xue Za Zhi. 2024. PMID: 39231766 Free PMC article. Chinese.

1. NCCN. The NCCN guidelines for acute lymphoblastic leukemia(version 1.2021)[DB/OL] https://www.nccn.org/professionals/physician_gls/pdf/all.pdf .
1. Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia[J] N Engl J Med. 2017;376(9):836–847. doi: 10.1056/NEJMoa1609783. - DOI - PMC - PubMed
1. Lejeune M, Köse MC, Duray E, et al. Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies[J] Front Immunol. 2020;11:762. doi: 10.3389/fimmu.2020.00762. - DOI - PMC - PubMed
1. Suryadevara CM, Gedeon PC, Sanchez-Perez L, et al. Are BiTEs the “missing link” in cancer therapy?[J] Oncoimmunology. 2015;4(6):e1008339. doi: 10.1080/2162402X.2015.1008339. - DOI - PMC - PubMed
1. Einsele H, Borghaei H, Orlowski RZ, et al. The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types[J] Cancer. 2020;126(14):3192–3201. doi: 10.1002/cncr.32909. - DOI - PubMed